• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Aims Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized, progressive,
and fatal cardiomyopathy, the natural history of which remains unclear. We sought to …

Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart
failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the …

Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with
a median survival from diagnosis, if untreated, ranging from< 6 months for light chain …

Background: Cardiac transthyretin amyloidosis (ATTR) is an increasingly recognized cause
of heart failure. Cardiac magnetic resonance (CMR), with late gadolinium enhancement …

Cardiac involvement drives prognosis and treatment choices in cardiac amyloidosis.
Echocardiography is the first-line examination for patients presenting with heart failure, and …